The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro

Wilke, Nicola L.; Abodo, Liliane Onambele; Frias, Corazon; Frias, Jerico; Baas, Jennifer; Jakupec, Michael A.; Keppler, Bernhard K.; Prokop, Aram

doi:10.1016/j.biopha.2022.113974

Cited by 6 publications

(7 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ga 3+ -metabolism stimulator; anticancer, antibacterial, anti-inflammation; Fe 3+ -mimetic Ga(NO 3 ) 3 in treatment of cancer-related hypercalcemia, 68 Ga-, 67 Ga-scintigraphy of malignant tumors, incl. Hodgkin's and non-Hodgkin's lymphomas Particularly nontoxic [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]…”

Section: Galliummentioning

confidence: 99%

Survey of Main Group Metals and Metalloids in Cancer Treatment

Kostova

2024

Inorganics

View full text Add to dashboard Cite

Cancer is one of the leading causes of human death among all major diseases. Metal-based complexes are considered as the most promising vital part in the existing arsenal of cytotoxic candidates used in cancer therapy and diagnostics. The efforts of many scientific groups resulted in the development of numerous metal-based compounds featuring different biologically active organic ligands in order to modulate their bioactivity. Along with the main representatives as potential therapeutic agents, such as the complexes Pt(II)/Pt(IV), Pd(II), Ru(II)/Ru(III), Ag(I), Au(I)/Au(III), Ti(IV), V(IV) and Ga(III), many other transition metal and lanthanide complexes possessing antiproliferative activity are widely discussed in the literature. However, such drugs remain outside the scope of this review. The main purpose of the current study is to review the potential activity of main group metal- and metalloid-based complexes against the most common cancer cell types, such as carcinomas (lung, liver, breast, kidney, gastric, colorectal, bladder, ovarian, cervical, prostate, etc.); sarcomas; blastomas; lymphomas; multiple myeloma; and melanoma. Overcoming the long disregard of organometallic compounds of metals and metalloids from the main groups, a growing number of emerging anticancer agents remarkably prove this field offers an extensive variety of new options for the design of innovative unexplored chemopharmaceutics. Moreover, some of the metal complexes and organometallic compounds from these elements can exhibit entirely different, specific modes of action and biological targets. Obviously, exploitation of their distinct properties deserves more attention.

show abstract

Section: Galliummentioning

confidence: 99%

Survey of Main Group Metals and Metalloids in Cancer Treatment

Kostova

2024

Inorganics

View full text Add to dashboard Cite

show abstract

“…A different study [ 95 ] focused on KP46 ( Figure 24 a) itself. It was tested against a variety of human cell lines: BJAB mock, including vincristine and doxorubicin-resistant; Nalm-6, including vincristine, etoposide and methotrexate-resistant strains; SK-N-AS and its vincristine-resistant subline; and K652.…”

Section: Novel Metal Complexes In Cancer Therapymentioning

confidence: 99%

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Todorov

Kostova

2023

Molecules

View full text Add to dashboard Cite

Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader “catch up” with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.

show abstract

“…Therefore, research has focused on substances that selectively induce apoptosis in malignant cells and at low concentrations. We and others have reported on novel metal-based compounds that can overcome these resistances and have a low toxicity [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ]. Metal complexes have long been of big interest in modern cancer research [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro

Wilke

Burmeister

Frias

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Moreover, HB324 showed synergistic activity with various established anticancer drugs and overcame resistance in several cell lines, such as neuroblastoma cells. In conclusion, HB324 showed promising potential as a novel anticancer agent in vitro, suggesting further investigations on this and other preclinical ruthenium drug candidates.

show abstract

The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro

Cited by 6 publications

References 80 publications

Survey of Main Group Metals and Metalloids in Cancer Treatment

Survey of Main Group Metals and Metalloids in Cancer Treatment

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs

Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro

Contact Info

Product

Resources

About